Zentiva

This page shows the latest Zentiva news and features for those working in and with pharma, biotech and healthcare.

Sanofi warns of difficult few months as diabetes sales slump

said that the last few months have included the pipeline-building acquisitions of Bioverativ and Ablynx and the sale of its Zentiva generics business to a private equity group.

Latest news

Sanofi appoints ex-Roche Reed as new R&D head

Brandicourt has also demonstrated his commitment to pursuing the core pharma business at Sanofi by selling off its Zentiva generics business for 1.9bn ($2.4bn).
Sanofi sells European generics to Advent for $2.4bn

Sanofi has been looking to divest the Zentiva generics unit since 2016 as part of restructuring the business under chief executive Olivier Brandicourt, who said: “Transferring this business to Advent is ... Sanofi bought the foundations of its European
Ten new medicines recommended in Europe

Duloxetine Zentiva (duloxetine) - a copycat of Lilly's Cymbalta - for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder, also saw a nod from the EMA.
Three cancer immunotherapies amongst new CHMP approvals

Finally, two generic medicines gained positive opinions: Bortezomib Accord (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma and Pregabalin Zentiva (pregabalin) for the treatment of epilepsy and generalised
Orphan drugs in latest CHMP recommendations

Completing the positive opinions were two new informed consent applications: Sevelamer carbonate Zentiva (sevelamer) from Genzyme for the control of hyperphosphataemia in adults receiving haemodialysis or peritoneal dialysis and Rasagiline

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest appointments

Karim Husny moves from Omega Pharma to Alliance Pharmaceuticals

He brings experience in over the counter and consumer healthcare having worked at several European pharmaceutical firms, including Laboratoire de la Mer, Pfizer and Sanofi's Zentiva business.
Watson selects global generics management team

Ramneborn has more than 20 years' experience in the pharmaceutical industry and joined Actavis from Zentiva, where he was vice president and a member of the board of directors since 2003.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Editorial Director – Medical Education: Neg

Senior Account Executive – Medical Communications: Salary TBC

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Experienced Editor, London, Medical Communications: Competitive package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Account Director – Global Healthcare PR: Salary TBC

Director Healthcare PR Communications: Salary TBC

Scientific Director: Highly Competitive Salary &Benefits

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Director – Head of Public Affairs: Neg

Associate Medical Director: Salary TBC

Account Director: Negotiable

Scientific Team Lead: Competitive Salary

Account Manager, Healthcare Advertising: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Project / Account Manager (Medical Education): Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Tackling a formidable foe: Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Cancer care – the power of new technologies: With patient numbers set to soar, how can we make a difference?...
Redefining communications excellence: How to be heard in today’s multichannel, multistakeholder, multimedia world...